ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the receipt of a $150,000 cash licensing payment from AiBtl BioPharma Inc., marking a significant milestone in their strategic partnership. This payment is part of a broader agreement aimed at the commercialization of ABVC's late-stage drug candidates, ABV-1504 and ABV-1505, targeting Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD) respectively. Both candidates have completed Phase II and Phase IIB clinical trials and hold active INDs with the U.S. Food and Drug Administration.
Dr. Uttam Patil, ABVC Chief Executive Officer, emphasized the importance of this milestone, stating it reflects the accelerating momentum behind the company's global licensing strategy and validates the value of its late-stage clinical assets. To date, ABVC has received a cumulative total of $846,000 in non-dilutive licensing income from partnerships with AiBtl, ForSeeCon, and OncoX, reinforcing its capital-efficient, partnership-driven business model.
ABVC's licensing agreements with multiple partners across North America and Asia, including AiBtl BioPharma Inc., ForSeeCon Eye Corporation, and OncoX BioPharma, Inc., highlight the company's commitment to developing innovative botanical drugs through Phase II/III and licensing out clinical-stage products for global expansion. These partnerships are expected to contribute significantly to ABVC's 2025 revenue stream, following a 234% increase in annual revenue and a 77% year-over-year improvement in earnings per share.
The growing demand for alternative and effective treatments for CNS disorders globally underscores the importance of ABVC and AiBtl's progress in botanical drug development. With nearly 300,000 patients in Australia expected to be affected by a serious drug shortage, the development of legal therapeutic alternatives is more urgent than ever. ABVC's licensing-first strategy not only positions the company as a leader in CNS-focused botanical therapeutics but also offers a timely solution to vulnerable patient populations in need.
